Shopping Cart
Remove All
Your shopping cart is currently empty
Vilanterol trifenatate is a long-acting agonist of β2-adrenoceptor (β2-AR) with inherent 24-hour activity(β2-AR, β1-AR and β3-AR pEC50s of 10.37, 6.98 and 7.36, respectively)

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $31 | - | In Stock | |
| 5 mg | $85 | - | In Stock | |
| 10 mg | $126 | - | In Stock | |
| 25 mg | $230 | - | In Stock | |
| 50 mg | $369 | - | In Stock | |
| 100 mg | $531 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $108 | - | In Stock |
| Description | Vilanterol trifenatate is a long-acting agonist of β2-adrenoceptor (β2-AR) with inherent 24-hour activity(β2-AR, β1-AR and β3-AR pEC50s of 10.37, 6.98 and 7.36, respectively) |
| Targets&IC50 | β2-adrenoceptor:10.37±0.05(pEC50) , β1-adrenoceptor:6.98±0.03(pEC50) , β3-adrenoceptor:7.36±0.03(pEC50) |
| In vivo | The preclinical pharmacological profile of vilanterol using radioligand binding and cAMP studies in recombinant assays as well as human and guinea pig tissue systems to characterize β(2)-AR binding and functional properties.?Vilanterol displayed a subnanomolar affinity for the β(2)-AR that was comparable with that of salmeterol but higher than olodaterol, formoterol, and indacaterol.?In cAMP functional activity studies, vilanterol demonstrated similar selectivity as salmeterol for β(2)- over β(1)-AR and β(3)-AR, but a significantly improved selectivity profile than formoterol and indacaterol.?Vilanterol also showed a level of intrinsic efficacy that was comparable to indacaterol but significantly greater than that of salmeterol. |
| Synonyms | GW642444 (trifenatate) |
| Molecular Weight | 774.77 |
| Formula | C44H49Cl2NO7 |
| Cas No. | 503070-58-4 |
| Smiles | OCc1cc(ccc1OC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1)[C@@H](O)CNCCCCCCOCCOCc1c(Cl)cccc1Cl |
| Relative Density. | no data available |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (129.07 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (2.58 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.